(Q36718901)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17255142%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

review article

1 reference

title

Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17255142%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17255142%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

Juan A. Pineda

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17255142%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

author name string

José A Mira

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17255142%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

language of work or name

English

0 references

publication date

25 January 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17255142%20AND%20SRC:MED&resulttype=core&format=json

Journal of Antimicrobial Chemotherapy

24 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17255142%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

volume

59

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17255142%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

page(s)

342-346

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17255142%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17255142%20AND%20SRC:MED&resulttype=core&format=json

Grade 4 Events Are as Important as AIDS Events in the Era of HAART

24 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL524

Adverse effects of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL524

Pitfalls of assessing hepatotoxicity in trials and observational cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL524

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL524

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL524

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL524

Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL524

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL524

Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL524

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL524

Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL524

Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL524

Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996–2001

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL524

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL524

Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL524

Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL524

Low incidence of hepatotoxicity in a cohort of HIV patients treated with lopinavir/ritonavir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL524

Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL524

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL524

Efficacy and toxicity of antiretroviral therapy using 4 or more agents: application of a strategy for antiretroviral management in human immunodeficiency virus-infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL524

Liver injury during highly active antiretroviral therapy: the effect of hepatitis C coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL524

Fosamprenavir: a review of its use in the management of antiretroviral therapy-naive patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL524

Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL524

Pulmonary hypersensitivity reaction induced by efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL524

Severe efavirenz-induced hypersensitivity syndrome (not-DRESS) with acute renal failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL524

Fulminant hepatic failure after the start of an efavirenz-based HAART regimen in a treatment-naive female AIDS patient without hepatitis virus co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL524

A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL524

Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL524

Liver toxicity caused by nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL524

No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL524

The relationship between nevirapine plasma concentrations and abnormal liver function tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL524

Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL524

Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL524

Hepatitis C in the HIV-Infected Person

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKL524

21 January 2018

Identifiers

DOI

10.1093/JAC/DKL524

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17255142%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

1 reference